VIDEO: Vevye ‘changing the landscape’ in treatment of dry eye
Click Here to Manage Email Alerts
CHICAGO — In this Healio Video Perspective from the AAO meeting, Ranjan P. Malhotra, MD, FACS, discusses how Vevye, a higher-concentration formulation of cyclosporine, is “changing the landscape” in dry eye.
Vevye (cyclosporine ophthalmic solution 0.1%, Harrow) addresses the tolerability issue faced by patients with dry eye, as it offers a nonburning, nonstinging therapy that works quickly to treat the signs and symptoms of dry eye within 2 weeks, according to Malhotra, of Ophthalmology Associates in the St. Louis area.
“It’s created a big splash, even though cyclosporine has been around for over 20 years,” he said. “This formulation of cyclosporine is not only a higher concentration, the vehicle makes it more bioavailable, and it translates clinically.”